NCT07544654 2026-04-22
A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Phase 3 Not yet recruiting
Boehringer Ingelheim
Sichuan Baili Pharmaceutical Co., Ltd.
Shanghai JMT-Bio Inc.
Shanghai Runshi Pharmaceutical Technology Co., Ltd